The circulating levels of FGF 21 are elevated in patients with NAFLD/NASH, insulin resistance and obesity42, and also in animal models of NASH and obesity, suggesting a state of FGF21 resistance under these conditions69. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.